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Introduction
Antithrombin (AT) is a plasma inhibitor of the serpin superfamily that regulates the proteolytic activity of coagulation proteases of the clotting cascade in both the intrinsic and the extrinsic pathways [1] [2] [3] [4] . It circulates in plasma at a concentration of~0.125 mg mL À1 (~2.5 lM), and its hereditary or acquired deficiency is associated with an increased risk of thrombosis [5, 6] . Complete AT deficiency in mice results in embryonic lethality [7] . AT is a heparinbinding serpin possessing a basic D-helix, and the binding of a distinct pentasaccharide (H5) sequence of heparin containing 3-O-sulfate (3-OS) modification to this helical motif induces a conformational change that activates the serpin, thereby improving its reactivity with vitamin Kdependent coagulation proteases by~100-500-fold [1, 8, 9] . Interestingly, however, the activation of AT by H5 plays a minimal role in promoting AT inhibition of thrombin, and longer-chain heparins are required to enhance protease inhibition by a bridging (template) mechanism [10] . This mechanism of heparin-mediated AT inhibition of coagulation proteases has been extensively studied by the use of in vitro assays. It has been traditionally assumed that this model of heparin-mediated coagulation protease inhibition by AT can also occur in vivo by AT binding to specific vascular heparan sulfate proteoglycans (HSPGs) lining the vessel wall. In support of this hypothesis, it has been shown that a small population of vascular HSPGs (1-5%) has glycosaminoglycans (GAGs) containing H5 sequences with the same characteristic 3-OS modification [11, 12] . Nevertheless, other than in the therapeutic setting, there are hardly any in vivo data in the literature to firmly support this mechanism of vascular GAG-mediated AT inhibition of coagulation proteases under different pathophysiologic conditions. In addition to its anticoagulant function through direct inhibition of procoagulant proteases, AT also possesses potent anti-inflammatory signaling activities [13] [14] [15] [16] . The anti-inflammatory function of AT is mediated through the same D-helix-dependent interaction of the serpin with 3-OS-containing vascular HSPGs [13] [14] [15] [16] [17] . In contrast to its poorly understood physiologic role in the anticoagulant pathway, the critical role of D-helix-dependent interaction of AT with 3-OS-containing vascular GAGs in the signaling function of the serpin has been relatively well established. Thus, results from numerous studies have indicated that the binding of AT to vascular GAGs elicits potent anti-inflammatory responses by inducing prostacyclin production that culminates in inhibition of nuclear factor-jB (NF-jB) activation, downregulation of the expression of vascular cell adhesion molecules, and inhibition of synthesis of proinflammatory cytokines [13] [14] [15] [16] [17] [18] . At least 12 distinct heparin-binding site (HBS) mutations of AT (type II deficiency) that are associated with a higher incidence of venous and/or arterial thrombosis have been thus far identified [5] . It has been demonstrated that progressive inhibitory activities of HBS mutants, purified from patient plasma, are minimally affected, so the underlying basis of thrombosis in carriers of these mutations has been primarily considered to be the loss of their heparin cofactordependent protease inhibitory function. The possible effects of such mutations on the anti-inflammatory function of HBS variants have not been investigated.
To address this question, we expressed two natural HBS variants of AT that are associated with a higher incidence of venous/arterial thrombosis in heterozygous and homozygous carriers [5, 19] . The two AT mutants have Ile7 to Asn (I7N, Rouen III) and Leu99 to Phe (L99F, Budapest III) substitutions, neither of which is actually located on the D-helix; nevertheless, both variants show low affinities for heparin [19] [20] [21] . Characterization of these recombinant AT mutants in this study revealed that both mutants have lost their anti-inflammatory signaling activities in response to proinflammatory stimuli as determined with several established assay systems. Computational and kinetic analysis predict a destabilizing effect of the L99F mutation on the structure of the serpin. The results of this proof-of-concept study support the hypothesis that loss of the D-helix-dependent signaling function of HBS variants may also contribute to enhanced thrombosis in carriers under certain pathophysiologic conditions.
Materials and methods

Expression and purification of AT variants
Recombinant human wild-type AT (AT-WT) was expressed in HEK-293 cells by use of the RSV-PL4 expression/purification vector system, as described previously [22] . The same vector system was used to prepare two AT variants in which Ile7 and Leu99 of the serpin were replaced with either Asn (AT-I7N) or Phe (AT-L99F) in two separate constructs. AT derivatives were purified to homogeneity from 20 L of cell culture supernatants by immunoaffinity chromatography with the HPC4 mAb linked to Affi-gel 10 (Bio-Rad, Hercules, CA, USA), as described previously [22] . Concentrations of AT derivatives were determined from the absorbance at 280 nm by use of a molar absorption coefficient of 37 700 M À1 cm À1 and by stoichiometric titration of serpins with calibrated concentrations of thrombin, as described previously [22, 23] . A complete list of other reagents and details of experimental methods are shown in Data S1.
Inhibition assays
Rates of inactivation of proteases by AT derivatives in both the absence and the presence of pentasaccharide (H5) and heparin were measured under pseudo-first-order rate conditions with a discontinuous assay method, and observed pseudo-first-order (k obs ) and second-order (k 2 (app) ) association rate constants for uncatalyzed and catalyzed reactions were calculated as described previously [22, 23] . This assay was also used to evaluate the thermal stability of AT derivatives (1 lM) after their incubation at 56°C for 0-60 min.
Permeability assay
EA.hy926 endothelial cell permeability in response to lipopolysaccharide (LPS) (15 ng mL À1 ) in the absence or presence of increasing concentrations of AT derivatives (0.67-5.0 lM for 4 h) was assessed by spectrophotometric measurement of the flux of Evans blue-bound albumin across functional cell monolayers with a modified twocompartment chamber model as described previously [24] .
NF-jB assay
The activation of NF-jB in nuclear lysates of LPS-treated endothelial cells with or without pretreatment with AT derivatives (0.67-2.5 lM, 4 h) was measured with an ELISA kit (Cell Signaling Technology, Danvers, MA, USA) according to the manufacturer's protocol.
In vivo permeability and leukocyte migration assays
Each group of mice (N = 10) was injected intraperitoneally with 200 lL of AT derivatives (0.04 mg g À1 body weight) or with 200 lL of normal saline as a control. After 3 h, 1% bovine serum albumin (BSA)-bound Evans blue dye in normal saline was injected intravenously, and this was followed by immediate intraperitoneal injection of LPS (2 mg kg À1 body weight). Thirty minutes later, mice were killed, peritoneal exudates were collected, and vascular permeability was measured according to leakage of dye (650 nm) into the peritoneal cavity [26] . For analysis of leukocyte migration, 20 lL of peritoneal fluid was mixed with 0.38 mL of Turk's solution (0.01% crystal violet in 3% acetic acid), and the number of leukocytes was counted under a light microscope [26] .
Statistical analysis
Data were expressed as means AE standard deviation from at least three independent experiments. Group data were compared by the use of ANOVA followed by Bonferroni post hoc tests (for comparisons among three or more groups) or Student's t-test, as appropriate. P-values of < 0.05 were considered to be statistically significant.
Structural analysis and estimation of DDG values
The two amino acid substitutions were investigated by the use of X-ray crystal structures of both native AT (Protein Data Bank [PDB] entry 2beh) [27] and pentasaccharide-activated AT (PDB entry 1azx) [28] , and of pentasaccharide-activated AT in complex with activated factor X (FXa)-S195A (PDB entry 2gd4) [29] , with the PYMOL molecular graphics system (Schr€ odinger, LLC, Cambridge, MA, USA). Residue interaction networks [30] were computed with RING [31] . Stability predictions (DDG values) upon mutations were estimated with three different and complementary approaches. The structurebased prediction engine DUET [32] , which combines two different methods, named mCSM and SDM (see Data S1), was used for analysis. Computations were also performed with the structure-based POPMUSIC method [33] , and with the sequence and structure-based INPS-MD approach [34] .
Results
Expression and characterization of AT derivatives determined with kinetic assays
The AT derivatives were expressed in HEK-293 cells, and purified to homogeneity by a combination of immunoaffinity and heparin-Sepharose chromatography [22] . In contrast to AT-WT, which eluted at~1 M NaCl from the heparin column, AT-I7N and AT-L99F were eluted at lower NaCl concentrations of~0.3 M and 0.5 M, respectively. These results are in agreement with previous observations that these mutants show much weaker affinity for heparin [5, [19] [20] [21] . Both mutants reacted with near-normal or slightly lower rate constants with both FXa and thrombin in the absence of a cofactor (Table 1) . Thus, the concentration dependence of AT inhibition of FXa yielded similar k obs (Fig. 1A ) and k 2 (app) values for inhibition of the protease by AT derivatives (Table 1) . However, both AT variants showed significantly lower rate constants for FXa in the presence of H5 (Fig. 1B) , thus yielding k 2(app) values that were approximately eight-fold (AT-I7N) and 47-fold (AT-L99F) lower than those for protease inhibition by AT-WT ( Table 1 ). The heparin concentration dependence of Table 1 Second-order rate, k 2(app) , and equilibrium dissociation, K D , constants for the inhibition of activated factor X (FXa) and thrombin by antithrombin (AT) derivatives in the absence and presence of heparins 
ND, not determined; H5, pentasaccharide. All k 2 values for the AT inhibition of FXa and thrombin were determined with a discontinuous assay, and K D values were determined from changes in the intrinsic protein fluorescence upon titration with heparins as described in Materials and methods. All values are averages of three independent measurements AE standard deviation.
inhibition of proteases by AT mutants (Fig. 1C,D) indicated that the reactivity of mutants with both FXa and thrombin was similarly impaired (Table 1) . Thus, at optimal concentrations of heparin (Fig. 1C,D) , the reactivity of AT-I7N with FXa and thrombin was impaired bỹ 13-fold and~20-fold, respectively ( Table 1) . The same values for the AT-L99F inactivation of both FXa and thrombin at optimal concentrations of heparin were lower than those for AT-WT by~40-fold ( Table 1) .
The binding of heparin to the D-helix of AT is associated with an enhancement of the intrinsic fluorescence intensity of the serpin [35] . Analysis of the heparin-dependent intrinsic protein fluorescence changes in AT-WT and AT-I7N yielded equilibrium dissociation constants (K D ) of 12.5 nM and 113 nM, respectively ( Fig. 2A ; Table 1 ). Thus, consistent with kinetic data, the affinity of AT-I7N for heparin was decreased by approximately an order of magnitude. The same results were obtained when K D values were measured for H5 binding to serpins; thus, AT-I7N showed approximately six-fold lower affinity for the pentasaccharide (Table 1 ). The same analysis for AT-L99F was not successful, because repeated experiments in Tris-buffered saline (ionic strength 0.1) with this mutant did not result in any significant intrinsic protein fluorescence change upon binding of heparin. These results suggested that the L99F mutation might be associated with dramatic structural changes in the mutant serpin. In agreement with this hypothesis, when we measured the inhibition rate constants, we noted that the stability of AT-L99F had been negatively affected. This was evidenced by AT-L99F showing lower and variable activity from day to day and upon freeze-thawing of the serpin. Moreover, < 10% of the protein recovered from the affinity column showed activity, even though the protein was essentially homogeneous on SDS-PAGE (data not shown). To investigate this question further, we compared the thermal stability of AT-L99F in a kinetic assay by incubating the serpin at 56°C and comparing its protease inhibitory activity with that of AT-WT. Analysis of the results supported our hypothesis that AT-L99F is highly unstable, because, unlike that of AT-WT, most of the inhibitory activity of AT-L99F was abolished by 60 min (Fig. 2B,C ). It appears that the rate of conversion of AT-L99F to the latent form had been markedly enhanced in the mutant serpin. These results suggested that the L99F mutation is associated with dramatic AT-L99F
[AT] nM The same as (C), except that the heparin concentration dependence of protease inhibition by AT-L99F was monitored. k 2(app) values from three independent measurements are shown in Table 1 . Th, thrombin. structural changes in the mutant serpin. Further analysis revealed that the apparent stoichiometry of inhibition (SI) by AT-L99F had also been elevated approximately two-fold to three-fold for thrombin and more than fivefold for FXa, suggesting that the reactivity of both proteases with the mutant serpin in the substrate pathway may have been increased. However, an accurate estimation of SI values proved to be challenging, as the inhibitory activity of the mutant was not stable during the incubation time, and, if heparin was included in the assay, the rate of the reaction in the substrate pathway for FXa was also increased. The I7N mutation did not cause an increase in the SI values with either protease (data not shown).
Structural analysis and estimation of DDG values
Ile7 is located in a turn in the N-terminal heparin-binding region of AT (Figs S1 and S2). The side chain of this residue is essentially solvent-exposed in the native AT structure, whereas it is more buried in the heparin-activated AT form (Fig. S1 ). This residue is next to the Cys8-Cys128 disulfide bond (Fig. 3A) . This region is partially flexible, and structural changes upon heparin binding were noticed (Fig. S2) . There is space to accommodate an Asn side chain in this environment, and in silico mutagenesis experiments performed with PYMOL showed that most of the known rotamers for Asn could fit in the native AT structure without creating severe atomic clashes (Fig. 3A) . The residue interaction networks ( Figs S3 and S4) show that Ile7 has a few noncovalent contacts with hydrophobic residues, and is near several positively charged residues present in this region of AT. The node degree (non-covalent interactions such as hydrogen bonds and van der Waals contacts) for Ile7 is small, having a value of 2. Several residues surrounding Ile7 also have a low node degree. In general, substitution of a residue with a small node degree in such an environment is predicted to be structurally tolerated. The predicted DDG stability changes for the I7N substitution were: DUET, À 0.91 kcal mol all methods suggest that the I7N substitution should be only moderately destabilizing (Fig. 3A) . Leu99 is located on the N-terminus of the C-helix, at some distance from the heparin-binding D-helix of the serpin (Fig. S1 ). Leu99 in all three different AT structures is buried (relative solvent accessibility of~3.6%) and located in a primarily hydrophobic environment (Figs S1 and S5). This region is stabilized by the Cys21-Cys95 disulfide bond, and the nearby Asn96 is glycosylated (Fig. 3B) . The b-factors on the C-helix are relatively low as compared with other regions of the protein, suggesting that the area is relatively rigid. There is little free space around position 99 to accommodate a larger side chain such as that of Phe. Thus, The image is centered on Ile7 (magenta). Ile7 was mutated to Asn in silico (lower corner). The side chain of the mutant residue is readily accommodated in the structure. The estimated stability changes upon mutation also suggest that the substitution could be tolerated, and the scores predict that the amino acid change is only slightly destabilizing. Right panel: a sequence logo was generated with the WEBLOGO sequence logo generator [43] . The AT sequences from five different species (human, mouse, bovine, sheep, and monkey) are shown. Ile7 is not fully conserved, but is generally replaced by a hydrophobic residue. (B) Structural analysis of Leu99 (in magenta). The side chains of selected residues surrounding Leu99 are shown in cyan, and a glycan side chain grafted onto Asn96 is shown in grey. Replacement of Leu99 by a Phe was carried out on in silico, and, for all of the available Phe rotamers, important steric clashes were noticed. These clashes are indicated by small red disks, and only the side chains of Leu99 (magenta) and of Phe (white), and the disulfide bond Cys21-Cys95, are shown, to simplify the figure. Right panel: the sequence logo shows that Cys95, Asn96, Thr98, Leu99, Gln101, Leu102, Leu103 and Glu104 are strictly conserved in the AT sequences. The estimated stability changes computed suggest that the substitution should be destabilizing. [Color figure can be viewed at wileyonlinelibrary.com]
Leu99 to Phe in silico mutagenesis performed with PYMOL, with or without energy minimization, showed severe steric clashes for all Phe rotamers available, not only with some surrounding side chains, but also, and mainly, with backbone atoms (Fig. 3B) . Analysis of the residue interaction networks (Figs S3 and S4) showed that Leu99 is, in part, surrounded by hydrophobic residues, and that it is involved in eight non-covalent interactions (node degree) with surrounding residues. Residues near Leu99 also tend to have relatively high node degrees. Substitution of such a residue is, in general, destabilizing, and can induce some severe local structural changes. This expected destabilization is further supported by the predicted DDG stability changes, as the L99F substitution led to a destabilizing score of À 1.7 kcal mol
À1
with the DUET method (mCSM, À 1.5 kcal mol À1 ; SDM, À 0.84 kcal mol À1 ), whereas for POPMUSIC it was + 0.9 kcal mol -1 (a positive DDG with this method indicates destabilization), and for INPS-MD it was À 0.97 kcal mol À1 (Fig. 3B) . 
Analysis of the anti-inflammatory activity of serpin variants
Next, the anti-inflammatory activity of serpin variants was evaluated with several established cell-based assays. LPS is known to induce activation of the nuclear transcription factor NF-jB, and disrupt the barrier permeability function of endothelial cells. We have demonstrated that AT has a protective effect in both assays, reversing LPS-mediated proinflammatory processes in a concentration-dependent manner [15] . Interestingly, unlike AT-WT, neither AT-L99F (Fig. 4A) nor AT-I7N (Fig. 4B) showed any modulatory effect on the NF-jB pathway in response to LPS. Similarly, neither AT-L99F (Fig. 5A ) nor AT-I7N (Fig. 5B) showed any barrier protective activity in the LPS-mediated barrier hyperpermeability assay. Analysis of LPS-mediated cell surface expression of cell adhesion molecules on endothelial cells pretreated with AT derivatives indicated that, unlike AT-WT, which inhibited the expression of both ICAM-1 and VCAM-1 in response to LPS, neither AT-L99F nor AT-I7N showed protective activity in these cellular assays (Fig. 6 ).
AT-WT but not AT-I7N inhibits the proinflammatory effect of LPS in vivo
A potent anti-inflammatory effect of AT has been observed in several in vivo inflammatory models [14, 16, 36, 37] . Here, we set up an LPS-mediated vascular permeability model by intraperitoneal injection of LPS into mice, and then measuring vascular permeability based on the extravasation of the BSA-bound Evans blue dye from plasma into the peritoneal cavity [26] . LPS dramatically increased endothelium leakiness, similarly to the effect of using a solution of 0.7% acetic acid as a positive control (Fig. 7) . Consistent with the literature [14, 36, 37] , AT-WT showed a therapeutic effect and inhibited LPSmediated vascular permeability, but AT-I7N showed no barrier protective activity in this model (Fig. 7A) . Similarly, AT-WT, but not AT-I7N, markedly inhibited LPS-mediated binding of leukocytes to the vascular endothelium and their subsequent migration to the peritoneal cavity (Fig. 7B) . A 1.5% carboxymethylcellulose-sodium solution was used as a positive control for leukocyte migration in this model [26] . The in vivo permeability study could not be conducted for AT-L99F, owing to our inability to prepare a sufficient quantity of active mutant, because, as described above, only a small fraction of the expressed protein showed activity, which was highly unstable and temperature-sensitive.
Discussion
AT deficiency has been phenotypically divided into type I deficiency (quantitative), which is characterized by equally low antigen and activity levels, and type II deficiency (qualitative), which is characterized by a lower activity level for the serpin [5] . Type II deficiency may be caused by a lower reactive center loop-dependent inhibitory activity of AT towards coagulation proteases and/or by loss of the heparin cofactor function because of mutations in the HBS of the serpin, which weakens its affinity for heparin [5] . The homozygous AT deficiencies of both types are not compatible with life, with the exception of two HBS mutations (L99F and R47C) that predispose the carriers to a higher incidence of thrombosis [5, 19, 20, 38, 39] . A recent clinical and laboratory study of a relatively large number of families carrying the L99F mutation established a founder effect for this mutation [19] . It has been found that both heterozygous and homozygous carriers of the L99F mutation experience a higher incidence of thrombosis, although the frequency and severity of the thrombosis in homozygous carriers were significantly higher [19] . Results from several laboratories using patient plasma-derived AT have established that the progressive inhibitory activity of AT-L99F against coagulation proteases is minimally affected but the capacity of the AT mutant to inactivate these proteases in the presence of heparin is diminished because of its lower affinity for heparin. The same results have been obtained with several other HBS mutants of AT (at least 12 have been identified), including a heterozygous patient who was found to carry an Ile7 to Asn substitution (AT-I7N) [21] . The underlying cause of thrombosis in such patients has been primarily considered to be the inability of these mutants to effectively regulate the proteolytic activity of procoagulant proteases of the clotting cascade, owing to their inability to interact with vascular GAGs, meaning, presumably, that they are not being able to optimally inhibit coagulation proteases. As all of the studies with the two HBS variants have been conducted with limited quantities of patient plasmaderived AT, we initiated this study and prepared sufficient amounts of recombinant serpin variants for a detailed characterization of their activities in different assay systems. Our results suggest that whereas, consistent with the published data, the progressive inhibitory activities of the serpin variants are not significantly affected, the protective signaling function of both variants is essentially eliminated. Thus, neither HBS variant under study showed protective anti-inflammatory activity in any one of the established cellular assays described above. Unlike AT-WT, neither of the AT variants was capable of inhibiting NF-jB activation or expression of cell adhesion molecules in endothelial cells in response to LPS. Neither mutant showed barrier protective activity in response to LPS. Moreover, AT-I7N did not show anti-inflammatory as means AE standard deviation. *P < 0.05, **P < 0.01. CMC-Na, carboxymethylcellulose-sodium.
activity in vivo in response to LPS-mediated barrier permeability dysfunction and inflammatory leukocyte infiltration. The in vivo experiments with AT-L99F were not feasible, owing to low recovery of the active form of this variant and its very poor stability. We found that the L99F mutation results in destabilization, temperature sensitivity, and an elevated rate of recognition of the serpin as a substrate by the coagulation proteases. Thus, the L99F mutation not only negatively affects the interaction of the D-helix with 3-OS-containing vascular GAGs, but also induces dramatic structural changes in the mutant serpin (see below). The 3-OS moiety of GAGs is added by the gene encoding heparan sulfate 3-O-sulfotransferase-1 (3-OST-1) [40] . Interestingly, it has been demonstrated that 3-OST-1-deficient mice have normal hemostasis, and show comparable phenotypes to those of wild-type mice in response to prothrombotic challenges [17, 41] . However, 3-OST-1-deficient mice show severe proinflammatory phenotypes in response to LPS challenge that unlike wild-type mice, are poorly ameliorated by exogenous AT, providing support for the hypothesis that interaction of AT with 3-OS-containing vascular GAGs may actually be responsible for the anti-inflammatory rather than the protease inhibitory function of AT [17, 41] . We also demonstrated that small interfering RNA knockdown of 3-OST-1 inhibits the protective signaling function of AT in cellular assays [16] . Recent targeting of the type II HBS variant, with the Arg47 to Cys mutation, to the mouse genome resulted in life-threatening spontaneous thrombosis, with only a fraction of mice surviving to adulthood [42] . Interestingly, the thrombin-AT (TAT) complex level in the transgenic mice was similar to that in the wild-type mice, possibly indicating that the inhibition of thrombin may not require interaction with GAGs. Thus, the traditional view, which is mostly based on in vitro and therapeutic heparin data, that AT binding to vascular GAGs is required for the AT regulation of coagulation proteases may require further investigation and validation, as we have not been able to find conclusive in vivo evidence in the literature that the vascular GAG-binding function of AT is required for its coagulation protease inhibitory function. In light of these results and the established concept that D-helix-dependent interaction of AT with 3-OS-containing GAGs elicits a potent barrier protective effect in vascular endothelial cells that might be essential for maintaining the vascular tone, the results of this study suggest that the higher incidence of thrombosis caused by HBS mutations may also be contributed to by the loss of the anti-inflammatory signaling function of AT under certain pathophysiologic conditions (i.e. acute infection). Thus, further investigation will be needed to determine the extent to which the conformational activation and/or a bridging effect of vascular GAG binding contributes to the protease inhibitory and antiinflammatory signaling functions of AT. We are in the process of developing appropriate model systems with which to investigate this important question.
Finally, the structural analysis of the effects of mutations by the use of several types of computational approaches suggest that the I7N substitution could be structurally tolerated, and that the defect is limited to the glycosylation of the mutant Asn [21] , which impedes the interaction of the serpin variant with heparin. In contrast, the structural analysis of AT-L99F indicated that the L99F mutation is highly destabilizing. Leu99 is buried in a relatively rigid environment on the C-helix, which also harbors the glycan-linked Asn96 and is stabilized by the Cys21-Cys95 disulfide bond (Fig. 3B) . Although Leu99, the Cys21-Cys95 disulfide bond and Asn96 are not conserved in the serpin family, they are nevertheless strictly conserved in the AT sequences from different species (Fig. 3B) , highlighting their importance in AT structure and function. There is little free space around position 99 to accommodate a larger side chain such as that of Phe. A Phe at this position would clash not only with nearby side chains but also with backbone atoms, most likely perturbing the folding of this area. It appears that this structural perturbation allosterically transmits the negative conformational effect of the mutation to the basic residues of the heparin-binding D-helix. Whether the L99F mutation alters the formation of the nearby disulfide bond and/or interferes with the linkage of a glycan side chain on Asn96 needs further investigation. The destabilizing effect predicted by this interactive structural analysis is further supported by the investigation of the residue interaction networks (Figs S3 and S4 ) and the DDG computational approaches, all of which suggest that the L99F mutation should be destabilizing. Thus, in addition to affecting the heparin affinity of the AT variant and eliminating its anti-inflammatory signaling properties, the L99F mutation decreases the thermal stability of the mutant serpin. 
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